echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > By 2020, the big health industry will reach 7.2 trillion industry tycoons "exploring the way"

    By 2020, the big health industry will reach 7.2 trillion industry tycoons "exploring the way"

    • Last Update: 2021-02-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Good wind by force, send me on the green clouds. "On November 24th, the 2017 China Pharmaceutical Capital Forum, hosted by the Daily Economic News, opened in Chengdu, taking advantage of the east wind of a new era of healthy China.
    more than 20 capitalists, industry leaders and more than 50 pharmaceutical listed companies from all over the country, more than 10 securities investment institutions of the industry elite, shared this annual feast of the pharmaceutical industry.Pharma industry market pattern is changing
    Guo Yunpei, president of the China Pharmaceutical Enterprise Management Association, attended the forum and delivered a speech, he mentioned that China is currently in an important period of transition from a pharmaceutical power to a pharmaceutical power, but at present, China's biopharmaceutical industry, small, scattered, chaotic situation, has not been fundamentally changed. The number of Chinese pharmaceutical companies is 5.6 times that of the United States, while the U.S. has a sales contribution of 5.76 times that of China.
    he also said that with the changes in the pharmaceutical industry structure, it is expected that next year there will be a larger industry reshuffle, a major restructuring, through the closure and transfer of the synthesis, five years later, the total number of Biopharmaceutical enterprises in China will be reduced by a quarter. In addition, the development of China's pharmaceutical listed companies is not balanced, the governance of listed companies also need to be improved, so improving the quality of operation of pharmaceutical listed companies, is the healthy development of the biopharmaceutical industry to make up for a lesson, is also a very important link.
    Liu Guoen, a professor of economics at Peking University's National Development Research Institute and director of Peking University's China Health Economic Research Center, said that the supply side of medical services is still partially stuck in the past administrative leadership and the system of resource allocation prices, tender stage, while under the "Healthy China" plan, the health of the Chinese should be fully life-cycle management, can not be limited resources single pressure on medical services, environmental protection, education, sports, agriculture sector should participate.
    china's pharmaceutical industry has entered a new era, the next 5 to 10 years is a key period of pharmaceutical development. Tao Jianhong, deputy director of the Southern Institute of Pharmaceutical Economics of the State Administration of Food and Drug Administration, said that by the time healthy China is realized in 2020, the total size of China's large health industry will reach 8% of GDP, with a total of more than 7.2 trillion yuan, which will be 2.5 times the current size.
    In recent years, various policies to vigorously promote the pharmaceutical industry, especially the development of innovative drugs, Tao Jianhong believes that in the future China will usher in a second wave of imported drugs, in the "two-vote system" background, the entire drug circulation industry in the past layer of agent distribution circulation mode will change, drug circulation industry will usher in a reshuffle, industry integration speed up. And the elderly and children's field, special medical food sector will be the future opportunity of the industry.recent years, medicine has become more and more important in the field of large
    consumption, and the dance between the pharmaceutical industry and capital has gradually entered a better situation.
    Qiushi, founding partner of Phoenix Investment, said china ranked 20th in the global biopharmaceutical competitiveness rankings in 2017, with BCI scoring 58 points. Although China's biopharmaceutical industry is relatively late, but China's biopharmaceutical market is expected to grow at an average rate of 18% in 2015-2020, higher than the global growth rate of 12%, because our country has given a high degree of support in terms of talent, capital and policy.
    also mentioned that domestic biologic drugs have segmentation opportunities in antibodies and cell therapy. China needs a reasonable and sound capital market classification platform in order to meet the financing needs of China's innovative pharmaceutical enterprises. In the next 5 years, China's biopharmacemic market has two key words: internationalization and innovation/imitation; (Daily Economic News Network)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.